Related Experiment Video
Updated: Sep 23, 2025
09:02
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
2.8K
Nanomedicines Targeting Glioma Stem Cells
Arjun Sabu1, Te-I Liu2, Siew Suan Ng1,3
1Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu 30013, Taiwan.
ACS Applied Materials & Interfaces
|May 11, 2022
Summary
Glioma stem cells (GSCs) drive glioblastoma (GBM) growth and treatment resistance. Targeting these cells with nanomedicines offers a promising strategy to improve GBM therapy and patient outcomes.
Area of Science:
- Neuro-oncology
- Cancer Stem Cell Biology
- Nanomedicine
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis.
- Glioma stem cells (GSCs) are key drivers of GBM's growth, resistance, and recurrence.
- Current therapies face challenges due to GSCs' self-renewal and differentiation capabilities.
Purpose of the Study:
- To review current knowledge on GSC-based therapies for GBM.
- To explore mechanisms underlying GSC-driven GBM.
- To highlight nanomedicines for GSC targeting in GBM treatment.
Main Methods:
- Review of existing research on GSC biology and GBM.
- Analysis of therapeutic strategies targeting GSCs.
- Evaluation of nanomedicine applications for GSC-targeted GBM therapy.
Main Results:
- GSCs are critical for GBM propagation, treatment resistance, and recurrence.
- Targeting GSC surface markers, signaling pathways, and niches are key anti-GSC strategies.
- Nanotechnology offers innovative approaches for GSC-specific drug delivery.
Conclusions:
- GSC-based therapies hold significant potential for improving GBM treatment.
- Nanomedicines provide novel avenues for precise GSC targeting.
- Further research into GSC-based nanotheranostics is crucial for advancing GBM care.
